Summary
Kissei Pharmaceutical Co., Ltd. researches, develops, manufactures, and sells pharmaceutical products primarily in Japan. The company offers Urief and Urief OD tablets for the treatment of dysuria; Glufast, Glubes, and Marizev tablets for type 2 diabetes; Darbepoetin Alfa BS and Epoetin Alfa BS injections for the treatment of renal anemia; Beova tablets for overactive bladder treatment; P-TOL chewable tablets for treating hyperphosphatemia; and Minirin Melt OD tablets for nocturia due to nocturnal polyuria in males, central diabetes insipidus, and nocturnal enuresis resulted from decrease of urine osmolality. Its products in pipeline include KPS-0373 that has completed Phase III clinical trial to treat spinocerebellar ataxia; CCX168, which has completed Phase III clinical trial for the treatment of microscopic polyangiitis and granulomatosis with polyangiitis; AJM300, which is in Phase III clinical trial to treat ulcerative colitis; R788 that is in Phase III clinical trial to treat chronic idiopathic thrombocytopenic purpura; and MR13A9, which is in Phase III clinical trial to treat uremic pruritus in dialysis patients. The company is also developing KLH-2109 for treating endometriosis and uterine fibroids; KDT-3594 for the treatment of Parkinson's disease; Silodosin for dysuria associated with benign prostatic hyperplasia; Mitiglinide for type 2 diabetes mellitus; and Bedoradrine for the treatment of acute exacerbation of asthma. In addition, it develops and sells protein controlled and energy supply foods; and purchases and sells related materials, as well as offers system development and information processing, construction contracting, equipment and facility management, and information gathering and development support services. The company was formerly known as Kissei Yakuhin Kogyo Co., Ltd. and changed its name to Kissei Pharmaceutical Co., Ltd. in October 1964. Kissei Pharmaceutical Co., Ltd. was incorporated in 1946 and is headquartered in Matsumoto, Japan.
History
The company was founded in 1960 and began operations as a regional drug manufacturer. In 1972, the company established a research and development lab in Tokyo and it expanded its operations to include manufacture and sales of active pharmaceutical ingredients and diagnostic reagents. In 2003, the company began selling drugs in Japan and has gradually expanded its operations both in Japan and abroad. In 2020, the company achieved a significant milestone by becoming the first Japanese drug manufacturer to reach $10 billion in net sales.
Mission
Our mission is to create drugs and diagnostic reagents that will help improve public health and to provide our products and services to people in need.
Vision
Our vision is to become a global pharmaceutical and medical technology leader, and to continue to strive for medical advances that will help people around the world.
Key Team
Mr. Yoshio Furihata (Sr. Advisor & Director)
Mr. Keiji Fukushima (Exec. VP & Director)
Mr. Tetsu Takayama (Exec. MD & Director)
Recognition and Awards
2011: Received Japan Quality Award from the Japan Quality Award Association
2018: Recognized as top pharmaceutical company by the Global Business Magazine’s annual rankings
2019: Received the Quality Excellence Award from the Healthcare Accreditation Association
References
